POSTERS & PUBLICATIONS
From the latest randomized trials and methodologies to solid research results, find all the information you need. Click on any media below to download.
Plinabulin and pegfilgrastim versus pegfilgastrim monotherapy after TAC: A comparison of efficacy, safety, relative dose intensity (RDI) and bone pain.
Protective 2 (BPI 2358 106): a Confirmatory Trial to Demonstrate Superiority of the Plinabulin (Plin) + Pegfilgrastim (Peg) Comb ination versus Standard of Care Pegfilgrastim for the Prevention of Chemotherapy Induced Neutropenia in Breast Cancer Patients.
Plinabulin is a more Favorable Option for the Prevention of Chemotherapy Induced Neutropenia (CIN) than Pegfilgrastimduring the COVID-19 Pandemic.
A Single IV Dose of Plinabulin Induces Sustained Mobilization of CD34+ Cells in Humans Through A Mechanism of Action Independent From G-CSF or CXCR4 and Without Causing Bone Pain or Thrombocytopenia
Adding Plinabulin (Plin) to Pegfilgrastim (Peg) Reverses the Immune Suppressive Potential of Peg while Offering Superior Prevention of Chemotherapy Induced Neutropenia (CIN) versus Peg Alone
A phase I trial of plinabulinin combination with nivolumaband ipilimumabin patients with relapsed small cell lung cancer (SCLC): Big Ten Cancer Research Consortium (BTCRC-LUN17-127) study
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.